BioMarin Pharmaceuticals BMRN Revenue
Revenue at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's revenue?
- BioMarin Pharmaceuticals (BMRN) reported revenue of $766.21M in Q1 2026.
- How has BioMarin Pharmaceuticals's revenue changed year-over-year?
- BioMarin Pharmaceuticals's revenue increased by 2.8% year-over-year, from $745.15M to $766.21M.
- What is the long-term trend for BioMarin Pharmaceuticals's revenue?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's revenue has grown at a 14.9% compound annual growth rate (CAGR), from $1.85B to $3.22B.